News

Please use the links below to view our latest press releases.

 

September 30, 2016

LEO Pharma expands partnering presence with LEO Science & Tech Hub in Boston

July 1, 2016

LEO Pharma enters biologics through strategic partnership with AstraZeneca

April 1, 2016

Astellas and LEO Pharma Close Transaction to Transfer Global Dermatology Business

November 11, 2015

LEO Pharma to acquire global dermatology portfolio from Astellas.

October 19, 2015

LEO Pharma Inc. Announces FDA Approval of Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% for Plaque Psoriasis 

August 3, 2015

LEO Pharma Supports the FDA’s Selection of Psoriasis as a Priority Disease

 June 8, 2015

LEO Pharma Inc. And Professional Football Player Jonathan Scott Partner To Increase Psoriasis Awareness

 November 13, 2014

New President and CEO of LEO US

 June 2, 2014

Change of leadership in the US

 January 25, 2012

FDA Approves PICATO® (ingenol mebutate) Gel, The First And Only Topical Actinic Keratosis (AK) Therapy With 2 Or 3 Consecutive Days Of Once-Daily Dosing

 January 11, 2012

LEO Pharma Inc. Debuts LEO® Quality Care Program for Plaque Psoriasis Patients 

 January 9, 2012

LEO Pharma A/S in-licenses compound from Virobay Inc. for development of investigational oral treatment of psoriasis

 December 22, 2011

LEO Pharma Inc. Expands US Presence, Adds Jobs

 October 11, 2011

LEO Pharma Inc. Hosts TRH the Crown Prince and Crown Princess at U.S./Danish "Building Bridges"/Skin Cancer Awareness Event

 July 15, 2011

LEO Pharma A/S and The Scripps Research Institute Enter Collaboration

 April 27, 2011

LEO Pharma Inc. Launches Enhanced Website for Taclonex® Plaque Psoriasis Treatments

 February 10, 2011

LEO Pharma Inc. Voluntarily Recalls innohep® (tinzaparin sodium injection) Multidose Vials